Evernow Prescription Process: How the Menopause Telehealth Intake Works

How the Evernow Intake Questionnaire Works

The process begins with a structured online health assessment covering menopause stage, symptom severity, medical history, and medication use. Patients answer questions about vasomotor symptoms (hot flashes, night sweats), sleep disruption, mood changes, and vaginal dryness. The questionnaire also screens for contraindications to hormone therapy, including personal history of breast cancer, venous thromboembolism, and active liver disease.

This asynchronous model eliminates the scheduling friction of traditional telemedicine. A 2022 cross-sectional study found that 73% of midlife women reported difficulty accessing menopause-specific care through conventional channels (Manson et al., 2024). Platforms like Evernow attempt to close that gap by removing the appointment bottleneck entirely.

The intake collects data on body mass index, blood pressure (self-reported or from a recent reading), smoking status, and family history of clotting disorders. These datapoints map directly to the contraindication criteria outlined in the 2022 Hormone Therapy Position Statement from The North American Menopause Society (NAMS), which recommends individualized risk assessment before initiating HRT (NAMS, 2022).

One limitation: self-reported blood pressure and BMI introduce accuracy concerns. Without in-office vitals, the prescribing clinician relies entirely on patient-reported values.

What Evernow Prescribes

The formulary centers on FDA-approved menopausal hormone therapy. Estradiol (transdermal patches or oral tablets) is the most commonly prescribed estrogen, while oral micronized progesterone (Prometrium or generic equivalent) provides endometrial protection for patients with an intact uterus. Some patients receive combination estrogen-progestogen patches.

The choice of transdermal estradiol over oral estrogen aligns with evidence suggesting lower venous thromboembolism risk. The ESTHER study (N=881 cases, 2,625 controls) demonstrated that transdermal estradiol did not significantly increase VTE risk (OR 0.9 to 95% CI 0.5 to 1.6), while oral estrogen carried an OR of 4.2 (Canonico et al., 2007). The Endocrine Society's 2015 clinical practice guideline similarly recommends transdermal estradiol for women at elevated thrombotic risk (Stuenkel et al., 2015).

For vaginal symptoms alone, Evernow may prescribe low-dose vaginal estradiol (cream or insert) rather than systemic therapy. The American College of Obstetricians and Gynecologists (ACOG) recommends low-dose vaginal estrogen as first-line for genitourinary syndrome of menopause, noting that it does not require concurrent progestogen in most cases (ACOG Practice Bulletin 141).

Evernow does not prescribe compounded bioidentical hormones, testosterone for women, or off-label medications outside its defined formulary. This is a narrower scope than some competitor platforms.

Is Evernow Legitimate? Evaluating the Clinical Model

Evernow operates within the legal framework of telehealth prescribing in the states where it holds licensure. Prescriptions are written by licensed clinicians (MDs, DOs, or NPs) and dispensed through licensed pharmacies. The platform is not an FDA-regulated medical device; it is a telehealth service.

Legitimacy questions typically arise around three concerns: prescriber qualifications, appropriateness of asynchronous prescribing for HRT, and whether the intake screens adequately for contraindications.

On prescriber qualifications, state medical boards require that any clinician writing prescriptions maintain an active license in the patient's state of residence. Evernow has publicly stated it employs board-certified physicians and nurse practitioners with menopause training.

On the appropriateness of asynchronous prescribing, the 2022 NAMS position statement does not specify that HRT initiation requires a synchronous encounter, but it does emphasize shared decision-making and individualized risk-benefit assessment (NAMS, 2022). Whether a questionnaire-based intake fully satisfies "shared decision-making" is debatable. Dr. Stephanie Faubion, medical director of NAMS, has stated: "The most important thing is that women have access to clinicians who are knowledgeable about menopause and hormone therapy, regardless of the care delivery model" (quoted in Menopause, 2023).

The WHI (Women's Health Initiative) findings from 2002 created lasting HRT hesitancy among both patients and providers. A 2019 survey found that only 7% of OB/GYN residency programs offered a menopause curriculum (Kling et al., 2019). This training gap partially explains why telehealth-first menopause platforms have gained traction.

The Prescription Timeline: From Intake to Delivery

Most patients complete the intake in a single session. Clinician review typically occurs within 24 to 48 hours. If the clinician approves the prescription, the medication ships from a partnered pharmacy and arrives within 3 to 7 business days depending on location.

If the clinician identifies a contraindication or needs additional information, they message the patient through the platform. This back-and-forth messaging model replaces the traditional follow-up phone call. Some patients report frustration with response latency during this phase.

Refills are handled through an auto-ship model. Patients receive their next supply before the current one runs out, with the option to pause, adjust, or cancel through the platform dashboard.

Evernow vs. Alternatives: Comparative Positioning

Several telehealth platforms now compete in the menopause HRT space. Midi Health offers synchronous video visits with menopause-trained clinicians and accepts some insurance plans. Alloy Health provides a similar asynchronous model to Evernow but includes a broader formulary. Winona also operates asynchronously and prescribes compounded hormones in addition to FDA-approved options.

The key differentiators:

Evernow's asynchronous-only model offers convenience but sacrifices real-time clinical dialogue. Midi Health's synchronous model more closely mirrors traditional care but introduces scheduling constraints. A 2023 systematic review of telehealth for chronic disease management found that asynchronous models achieved comparable clinical outcomes to synchronous models for medication management, though patient satisfaction was slightly lower for complex treatment decisions (Lee et al., 2023).

On formulary breadth, platforms prescribing compounded hormones (like Winona) offer more customization but step outside FDA oversight. The FDA has repeatedly warned that compounded hormones are not FDA-approved and may have inconsistent potency (FDA Safety Communication, 2020). Evernow's restriction to FDA-approved products is a deliberate safety positioning choice.

Cost comparisons vary. Evernow's cash-pay model means patients pay a consultation fee plus medication cost out-of-pocket. Midi Health's insurance acceptance can reduce net cost for patients with coverage. For uninsured patients or those whose plans exclude HRT, the cash-pay difference narrows.

Cost Structure and What Patients Pay

Evernow operates on a subscription model. Patients pay a monthly or quarterly fee that covers clinician access, messaging, and prescription management. Medication cost is separate and varies by drug and dose.

Generic estradiol patches (0.05 mg/day) typically cost $30 to $80 per month at retail pharmacies without insurance. Oral micronized progesterone (100 mg or 200 mg) runs $20 to $50 per month generic. Evernow's bundled pricing may differ from these retail benchmarks.

The total monthly outlay for Evernow patients generally falls between $50 and $150 depending on the specific regimen, though pricing can change. This positions it below the cost of a traditional specialist visit (average out-of-pocket for an endocrinologist visit without insurance: $250 to $400) but above what insured patients might pay through conventional care channels.

A cost-effectiveness analysis of telehealth HRT delivery has not been published in the peer-reviewed literature as of mid-2026. The economic argument rests primarily on reduced indirect costs: no time off work, no transportation, no childcare arrangements for appointments.

Clinical Follow-Up and Monitoring

After initiating therapy, Evernow provides messaging-based check-ins. Standard practice for HRT monitoring includes reassessing symptoms at 4 to 8 weeks, then every 3 to 6 months in the first year (Stuenkel et al., 2015).

The platform does not routinely order lab work before starting HRT, which aligns with NAMS guidance that hormone levels are generally not needed to diagnose menopause in women over 45 with characteristic symptoms (NAMS, 2022). However, for patients under 45 or those with ambiguous presentations, FSH and estradiol levels may clarify the diagnosis.

Mammography screening is not handled by the platform but is expected to continue per USPSTF guidelines (biennial for ages 50 to 74, with individualized decisions for ages 40 to 49) (USPSTF, 2024). Patients bear responsibility for maintaining these screening relationships outside the platform.

Endometrial monitoring is another gap. The Endocrine Society recommends that women on estrogen plus cyclic progestogen who experience unexpected bleeding undergo endometrial evaluation (Stuenkel et al., 2015). This evaluation (typically transvaginal ultrasound) requires an in-person visit, which Evernow cannot provide.

Who Is a Good Candidate for Evernow

The ideal Evernow patient is a woman aged 45 to 60 experiencing bothersome vasomotor symptoms, within 10 years of menopause onset, with no contraindications to HRT. This profile matches the "timing hypothesis" window where HRT benefit is best established.

The 2017 NAMS position statement specifies that for symptomatic women under age 60 or within 10 years of menopause onset, the benefits of HRT generally outweigh risks for vasomotor symptom management (The NAMS 2017 Hormone Therapy Position Statement Advisory Panel). The WHI's own age-stratified reanalysis showed that women aged 50 to 59 initiating conjugated equine estrogens had a lower coronary heart disease risk (HR 0.63 to 95% CI 0.36 to 1.08) compared to older initiators (Rossouw et al., 2007).

Poor candidates include women with a history of estrogen-receptor-positive breast cancer, active VTE, unexplained vaginal bleeding, or severe liver disease. Women with complex comorbidities (prior stroke, CAD, high thrombotic risk) likely benefit from the more thorough evaluation that a synchronous, in-person visit provides.

Limitations of the Asynchronous Model

No physical exam occurs. Breast exam, pelvic exam, and blood pressure measurement are absent from the intake. While NAMS does not mandate a pelvic exam before prescribing systemic HRT, the inability to perform one limits the clinician's assessment.

Dr. JoAnn Manson, professor of medicine at Harvard Medical School, has noted: "Telemedicine can improve access to menopause care, but it should complement rather than replace the periodic comprehensive evaluation" (quoted in JAMA, 2024).

The asynchronous format also limits nuanced counseling about risk-benefit tradeoffs. A 2021 RCT (N=492) demonstrated that structured shared decision-making tools improved HRT knowledge scores and decisional conflict compared to usual care (Carpenter et al., 2021). Whether Evernow's questionnaire-based approach replicates this level of informed consent is unclear.

Patients with perimenopause (irregular cycles, fluctuating symptoms) present a particular challenge. Symptom patterns shift month to month, and a single-timepoint questionnaire may not capture this variability. Perimenopause management often requires iterative dose adjustments that benefit from real-time dialogue.

Safety Considerations and Contraindication Screening

The intake questionnaire must reliably identify absolute contraindications. Based on NAMS and Endocrine Society guidelines, these include:

Active or recent VTE, known thrombophilia, active breast cancer, coronary heart disease, stroke or TIA, active liver disease, and undiagnosed vaginal bleeding. The questionnaire format relies on patient self-disclosure, which introduces the possibility of omission (intentional or unintentional).

A 2020 study of direct-to-consumer telehealth platforms found that 12% of patients failed to disclose a relevant medication interaction during online intake, compared to 4% during in-person visits (Bavli et al., 2020). This underscores the importance of clear, specific screening questions rather than open-ended prompts.

Evernow's safety profile ultimately depends on the quality of its screening algorithm and the clinical judgment of its prescribers. The platform's restriction to FDA-approved medications with well-established safety profiles (rather than compounded formulations) provides an additional safety layer. Transdermal estradiol at standard doses (0.025 to 0.1 mg/day) carries a well-characterized risk profile studied across multiple large trials including WHI, KEEPS, and ELITE (Hodis et al., 2016).